TL;DR
In the present cohort, 0.01% atropine suppressed myopia progression over 12 months, with inhibition ratios similar to previous trials involving mild to moderate myopia, which support the feasibility of low-dose atropine for advanced myopia and justify full-scale trials.
Purpose To determine which subgroup of children would best benefit from 0.01% atropine eyedrop. Methods This post hoc secondary analysis assessed 68 subjects. Placebo for the first year and 0.01% atropine eye drops for the second year. According to the annual spherical equivalent progression (SEP) during the first year...
This study aimed to compare the effects of three dosing frequencies of 0.05% atropine on the ocular surface in children with myopia. In this sub-analysis of a randomized controlled trial, children with myopia (aged 6–14 years) were randomized to 0.05% atropine once daily (Qd), twice weekly (Biw), or once weekly (Qw). O...
OBJECTIVE To compare the preventive effect of daily repeated low-level red light (RLRL) and 0.01% low-dose atropine eye drops (LDA) on myopia. METHODS This was a 12-month prospective comparative study. 216 Children aged 7-12 years using either RLRL or LDA for myopia prevention were enrolled between July 10, 2024 to A...
Introduction: Low-dose atropine (0.01%) has a promising pharmacological effect for slowing pediatric myopia progression. Yet, its specific efficacy and safety profile require ongoing evaluation. Methods: Following PRISMA guidelines and a PROSPERO registered protocol, this systematic review and meta-analysis analyzed ra...
Introduction: Myopia is the most prevalent refractive disorder of childhood, projected to approach 50% of the population by 2050. Low-dose atropine (0.01–0.05%) is the most investigated pharmacological intervention to slow myopia progression. Methods: A systematic review and meta-analysis was conducted per PRISMA 2020,...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
